Table 1 Clinical characteristics, serum biomarkers, and disease activities at week 0 of all patients with IBD (n = 184).

From: Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease

Variables

 

Sex, male, n (%)

121 (65.8)

Age (years), median [IQR]

40 [27–50]

Body mass index (kg/m2), median [IQR]

20.5 [18.5–23.4]

Smoking status, current/past, n (%)

24 (13.0)/30 (16.3)

Disease, CD/UC, n (%)

104 (56.5)/80 (43.4)

Disease duration (years), median [IQR]

6.0 [1.0–14.0]

Disease location in CD, ileitis/colitis/ileocolitis, n (%)

19 (18.3)/16 (15.4)/69 (66.3)

Perianal lesion in CD, n (%)

54 (51.9)

Disease location in UC, left-sided/extensive, n (%)

16 (20.0)/64 (80.0)

Biologic agents, UST/IFX/ADA, n (%)

119 (64.7)/33 (17.9)/32 (17.4)

Biologic exposure/ Anti-TNF exposure, n (%)

58 (31.5)/ 57 (31.0)

Concomitant drugs

 Corticosteroids, n (%)

63 (34.2)

 Immunomodulators, n (%)

64 (34.8)

 0w-LRG (µg/mL), median [IQR]

18.2 [12.5–28.1]

 0w-CRP (mg/dL), median [IQR]

0.19 [0.03–0.77]

 0w-Alb (g/dL), median [IQR]

3.9 [3.3–4.3]

 CDAI in CD, mean (SD)

162.8 (92.6)

 CDEIS in CD, median [IQR], n = 69

9.4 [5.5–17.0]

 PMS in UC, median [IQR]

5 [3–6]

 MES in UC, median [IQR], n = 54

2 [2–3]

  1. IBD inflammatory bowel disease, IQR inter-quartile range, CD, Crohn’s disease, UC ulcerative colitis, UST ustekinumab, IFX infliximab, ADA adalimumab, TNF tumor necrosis factor, LRG leucine-rich alpha-2 glycoprotein, 0w-LRG serum LRG level at week 0, CRP C-reactive protein, Alb Albumin, 0w-Alb serum Alb level at week 0, 0w-CRP serum CRP level at week 0, CDAI Crohn’s disease activity index, CDEIS Crohn’s disease endoscopic index of severity, SD standard deviation, PMS partial Mayo score, MES Mayo endoscopic subscore.
Back to article page